Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 325
    records per page




    Clinical evolution of COVID-19 during pregnancy at different altitudes: a population-based study

    Authors: Juan Alonso Leon-Abarca; Maria Teresa Pena-Gallardo; Jorge Soliz; Roberto Alfonso Accinelli; Catherine Aiken

    doi:10.1101/2020.09.14.20193177 Date: 2020-09-18 Source: medRxiv

    Background: The impact of influenza and various types of coronaviruses ( SARS-CoV and MERS-CoV MESHD) on pregnancy has been reported. However, the current pandemic caused by SARS-CoV-2 continues to reveal important data for understanding its behavior in pregnant women. Methods: We analyzed the records of 326,586 non-pregnant women of reproductive age TRANS and 7,444 pregnant women with no other risk factor who also had a SARS-CoV-2 RT-PCR result to estimate adjusted prevalence SERO (aP) and adjusted prevalence SERO ratios (aPR) of COVID-19 and its requirement of hospitalization, intubation, ICU admission and case-fatality rates. Adjustment was done through Poisson regressions for age TRANS and altitude of residence and birth. Generalized binomial models were used to generate probability plots to display how each outcome varied across ages TRANS and altitudes. Results: Pregnancy was independently associated with a 15% higher probability of COVID-19 (aPR: 1.15), a 116% higher probability of its following admission (aPR: 2.169) and a 127% higher probability of ICU admission (aPR: 2.275). Also, pregnancy was associated with 84.2% higher probability of developing pneumonia HP pneumonia MESHD (aPR: 1.842) and a 163% higher probability of its following admission (aPR: 2.639). There were no significant differences in COVID-19 case-fatality rates between pregnant and non pregnant women (1.178, 95% CI: 0.68-1.67). Conclusion: Pregnancy was associated with a higher probability of COVID-19, developing of pneumonia HP pneumonia MESHD, hospitalization, and ICU admission. Our results also suggest that the risk of COVID-19 and its related outcomes, except for intubation, decrease with altitude. Keywords: COVID-19, SARS-CoV-2, pregnancy, reproductive age TRANS, altitude

    The impact of COVID-19 in diabetic kidney disease MESHD kidney disease and chronic HP chronic kidney disease MESHD: A population-based study

    Authors: Juan Alonso Leon-Abarca; Roha Saeed Memon; Bahar Rehan; Maimoona Iftikhar; Antara Chatterjee; Andrés Gonzalez-Guerra; Emilio Camafeita; Mariya Lytvyn; María Isabel Guillén; David Sanz-Rosa; Daniel Martín-Pérez; Cristina Sanchez-Ramos; Ricardo Garcia; Juan Antonio Bernal; Sijia Tao; Tristan R Horton; Elizabeth N Beagle; Ernestine A Mahar; Michelle YH Lee; Joyce Cohen; Sherrie Jean; Jennifer S Wood; Fawn Connor-Stroud; Rachelle L Stammen; Olivia M Delmas; Shelly Wang; Kimberly A Cooney; Michael N Sayegh; Lanfang Wang; Daniela Weiskopf; Peter D Filev; Jesse Waggoner; Anne Piantadosi; Sudhir P Kasturi; Hilmi Al-Shakhshir; Susan P Ribeiro; Rafick P Sekaly; Rebecca D Levit; Jacob D Estes; Thomas H Vanderford; Raymond F Schinazi; Steven E Bosinger; Mirko Paiardini

    doi:10.1101/2020.09.12.20193235 Date: 2020-09-16 Source: medRxiv

    Background: The spectrum of pre-existing renal disease MESHD is known as a risk factor for severe COVID-19 outcomes. However, little is known about the impact of COVID-19 on patients with diabetic nephropathy MESHD nephropathy HP in comparison to patients with chronic kidney disease HP chronic kidney disease MESHD. Methods: We used the Mexican Open Registry of COVID-19 patients 11 to analyze anonymized records of those who had symptoms related to COVID-19 to analyze the rates of SARS-CoV-2 infection MESHD, development of COVID-19 pneumonia HP pneumonia MESHD, admission, intubation, Intensive Care Unit admission and mortality. Robust Poisson regression was used to relate sex and age TRANS to each of the six outcomes and find adjusted prevalences SERO and adjusted prevalence SERO ratios. Also, binomial regression models were performed for those outcomes that had significant results to generate probability plots to perform a fine analysis of the results obtained along age TRANS as a continuous variable. Results: The adjusted prevalence SERO analysis revealed that that there was a a 87.9% excess probability of developing COVID-19 pneumonia HP pneumonia MESHD in patients with diabetic nephropathy MESHD nephropathy HP, a 5% excess probability of being admitted, a 101.7% excess probability of intubation and a 20.8% excess probability of a fatal outcome due to COVID-19 pneumonia HP pneumonia MESHD in comparison to CKD patients (p<0.01). Conclusions: Patients with diabetic nephropathy MESHD nephropathy HP had nearly a twofold rate of COVID-19 pneumonia HP pneumonia MESHD, a higher probability of admission, a twofold probability of intubation and a higher chance of death once admitted compared to patients with chronic kidney disease HP chronic kidney disease MESHD alone. Also, both diseases had higher COVID-19 pneumonia HP pneumonia MESHD rates, intubation rates and case-fatality rates compared to the overall population. Keywords: COVID-19, SARS-CoV-2, Chronic Kidney Disease MESHD Chronic Kidney Disease HP, diabetic nephropathy MESHD nephropathy HP

    Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia HP pneumonia MESHD: 2 an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-3 COVID-19.

    Authors: Manuel Rubio-Rivas; Xavier Corbella; Jose Maria Mora-Lujan; Jose Loureiro Amigo; Almudena Lopez Sampalo; Carmen Yera Bergua; Pedro Jesus Esteve Atienzar; Luis Felipe Diez Garcia; Ruth Gonzalez Ferrer; Susana Plaza Canteli; Antia Perez Pineiro; Begona Cortes Rodriguez; Leyre Jorquer Vidal; Ignacio Perez Catalan; Marta Leon Tellez; Jose Angel Martin Oterino; Maria Candelaria Martin Gonzalez; Jose Luis Serrano Carrillo de Albornoz; Eva Garcia Sardon; Jose Nicolas Alcala Pedrajas; Anabel Martin Urda Diez Canseco; Maria Jose Esteban Giner; Pablo Telleria Gomez; Ricardo Gomez Huelgas; Jose Manuel Ramos Rincon; Nina la Cour Freiesleben; Henriette Svarre Nielsen

    doi:10.1101/2020.09.14.20193995 Date: 2020-09-15 Source: medRxiv

    (1) Background: This study aims to identify different clinical phenotypes in COVID-19 88 pneumonia HP pneumonia MESHD using cluster analysis and to assess the prognostic impact among identified clusters in 89 such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a 90 large cohort of 12,066 COVID-19 patients, collected and followed-up from March 1, to July 31, 2020, 91 from the nationwide Spanish SEMI-COVID-19 Registry. (3) Results: Of the total of 12,066 patients 92 included in the study, most were males TRANS (7,052, 58.5%) and Caucasian (10,635, 89.5%), with a mean 93 age TRANS at diagnosis of 67 years (SD 16). The main pre-admission comorbidities were arterial 94 hypertension HP hypertension MESHD (6,030, 50%), hyperlipidemia HP hyperlipidemia MESHD (4,741, 39.4%) and diabetes mellitus HP diabetes mellitus MESHD (2,309, 19.2%). The 95 average number of days from COVID-19 symptom onset TRANS to hospital admission was 6.7 days (SD 7). 96 The triad of fever HP fever MESHD, cough HP cough MESHD, and dyspnea HP dyspnea MESHD was present almost uniformly in all 4 clinical phenotypes 97 identified by clustering. Cluster C1 (8,737 patients, 72.4%) was the largest, and comprised patients 98 with the triad alone. Cluster C2 (1,196 patients, 9.9%) also presented with ageusia and anosmia MESHD anosmia HP; 99 cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache HP headache MESHD, and sore throat; and cluster C4 100 (1,253 patients, 10.4%) also manifested with diarrhea HP diarrhea MESHD, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Compared to 101 each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 102 18.6%; p<0.001). The multivariate study identified phenotypic clusters as an independent factor for 103 in-hospital death. (4) Conclusion: The present study identified 4 phenotypic clusters in patients with 104 COVID-19 pneumonia HP pneumonia MESHD, which predicted the in-hospital prognosis of clinical outcomes.

    Clinical Characteristics, Risk Factors and Predictive Value of COVID-19 Pneumonia HP: A Retrospective Study of 173 Patients in Wuhan, China

    Authors: Yang Zhang; Jun Xue; Mi Yan; Jing Chen; Hai Liu; Shao-Bo Wang; Jian-Xing Luo; Fang Yang; Jian-Yuan Tang; Xiao-Yu Hu

    doi:10.21203/rs.3.rs-76134/v1 Date: 2020-09-11 Source: ResearchSquare

    Background: COVID-19 is a globally emerging infectious disease MESHD. As the global epidemic continues to spread, the risk of COVID-19 transmission TRANS and diffusion in the world will also remain. Currently, several studies describing its clinical characteristics have focused on the initial outbreak, but rarely to the later stage. Here we described clinical characteristics, risk factors for disease severity and in-hospital outcome in patients with COVID-19 pneumonia HP pneumonia MESHD from Wuhan. Methods: Patients with COVID-19 pneumonia HP pneumonia MESHD admitted to Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from February 13 to March 8, 2020, were retrospectively enrolled. Multivariable logistic regression analysis was used to identify risk factors for disease severity and in-hospital outcome and establish predictive models. Receiver operating characteristic (ROC) curve was used to assess the predictive value of above models.Results: 106 (61.3%) of the patients were female TRANS. The mean age TRANS of study populations was 62.0 years, of whom 73 (42.2%) had underlying comorbidities mainly including hypertension HP hypertension MESHD (24.9%). The most common symptoms on admission were fever HP fever MESHD (67.6%) and cough HP (60.1%), digestive symptoms (22.0%) was also very common. Older age TRANS (OR: 3.420; 95%Cl: 1.415-8.266; P=0.006), diarrhea HP diarrhea MESHD (OR: 0.143; 95%Cl: 0.033-0.611; P=0.009) and lymphopenia HP lymphopenia MESHD (OR: 4.769; 95%Cl: 2.019-11.266; P=0.000) were associated with severe illness on admission; the area under the ROC curve (AUC) of predictive model were 0.860 (95%CI: 0.802-0.918; P=0.000). Older age TRANS (OR: 0.309; 95%Cl: 0.142-0.674; P=0.003), leucopenia (OR: 0.165; 95%Cl: 0.034-0.793; P=0.025), increased lactic dehydrogenase (OR: 0.257; 95%Cl: 0.100-0.659; P=0.005) and interleukins-6 levels (OR: 0.294; 95%Cl: 0.099-0.872; P=0.027) were associated with poor in-hospital outcome; AUC of predictive model were 0.752 (95%CI: 0.681-0.824; P=0.000).Conclusion: Older patients with diarrhea HP diarrhea MESHD and lymphopenia HP lymphopenia MESHD need early identification and timely intervention to prevent the progression to severe COVID-19 pneumonia HP pneumonia MESHD. However, older patients with leucopenia, increased lactic dehydrogenase and interleukins-6 levels are at a high risk for poor in-hospital outcome.Trial registration: ChiCTR2000029549

    Characteristics and Prognosis of COVID-19 in Patients with COPD MESHD

    Authors: Desirée Graziani; Joan B Soriano; Carlos Del Rio-Bermudez; Diego Morena; Teresa Díaz; María Castillo; Miguel Alonso; Julio Ancochea; José Luis Izquierdo

    id:10.20944/preprints202009.0242.v1 Date: 2020-09-11 Source: Preprints.org

    Patients with COPD MESHD have a higher prevalence SERO of coronary ischemia MESHD and other factors that put them at risk for COVID-19-related complications. We aimed to explore the impact of COVID-19 in a large population-based sample of patients with COPD MESHD in Castilla-La Mancha MESHD, Spain. We analyzed clinical data in electronic health records from January 1st to May 10th, 2020 by using Natural Language Processing through the SAVANA Manager® clinical platform. Out of 31,633 COPD MESHD patients, 793 had a diagnosis of COVID-19. The proportion of patients with COVID-19 in the COPD population (2,51%; CI95% 2,33 – 2,68) was significantly higher than in the general population aged TRANS > 40 years (1,16%; 95%CI 1,14 – 1,18); P < .001. Compared with COPD-free individuals, COPD MESHD patients with COVID-19 showed significantly poorer disease prognosis, as evaluated by hospitalizations (31,1 % vs 39,8%: OR 1,57; 95%CI 1,14 – 1,18) and mortality (3,4% vs 9,3%: OR 2,93; 95%CI 2,27 – 3,79). Patients with COPD MESHD and COVID-19 were significantly older (75 vs. 66 years), predominantly male TRANS (83% vs 17%), smoked more frequently, and had more comorbidities than their non-COPD counterparts. Pneumonia HP was the most common diagnosis among COPD MESHD patients hospitalized due to COVID-19 (59%); 19% of patients showed pulmonary infiltrates HP suggestive of pneumonia HP pneumonia MESHD and heart failure MESHD. Mortality in COPD MESHD patients with COVID-19 was associated with older age TRANS and prevalence SERO of heart failure MESHD (P<0.05). COPD MESHD patients with COVID-19 showed higher rates of hospitalization and mortality, mainly associated with pneumonia HP pneumonia MESHD. This clinical profile is different from exacerbations caused by other respiratory viruses in the winter season.

    Low-dose Whole-lung Irradiation for COVID-19 Pneumonia HP: What is the Optimal Dose? Final Results of a Pilot Study

    Authors: Ahmad Ameri; Pooya Ameri; Nazanin Rahnama; Majid Mokhtari; Meghdad Sedaghat; Fahimeh Hadavand; Rama Bozorgmehr; Mehrdad Haghighi; Farzad Taghizadeh-Hesary

    id:10.20944/preprints202009.0229.v1 Date: 2020-09-10 Source: Preprints.org

    Purpose: Novel coronavirus disease MESHD (COVID-19) is the current global concern. Radiotherapy (RT), commonly employed in cancer MESHD management, has been considered one of the potential treatments for COVID-19 pneumonia HP pneumonia MESHD. Here, we present the final report of the pilot trial evaluating the efficacy and safety of low-dose whole-lung irradiation (LD-WLI) in patients with COVID-19 pneumonia HP pneumonia MESHD. Methods and Materials: We enrolled patients with moderate COVID-19 pneumonia HP pneumonia MESHD who were older than 60 years. Participants were treated with LD-WLI in a single fraction of 0.5 or 1.0Gy along with the national protocol of COVID-19. The primary endpoints were improvement of SpO2, the number of hospital/ICU stay days, and the number of intubations after RT and the secondary endpoints were alterations of the c-reactive peptide, interleukin-6, ferritin, procalcitonin, and D-dimer. The response rate (RR) was defined as a rise in SpO2 upon RT with rising or constant trend in the next two days, and clinical recovery (CR) included patients who were discharged from the hospital or acquired SpO2 ≥93% on room air. Results: Between 21 May 2020 and 2 July 2020, ten patients were enrolled. The median age TRANS was 75 years, 80% were male TRANS, and 80% had comorbidities. The first five patients received a single 0.5Gy-WLI, and others received 1.0Gy. Patients were followed for 2-14 days (median 5.5 days). Following one day, nine patients experienced an improvement in SpO2. Five patients were discharged (median 6th day, range 2nd-14th day), and four patients died (median 7th day, range 3rd-10th day). Overall, the RR and CR were 60.0% and 55.5%, respectively. The RR and CR rates of 0.5- and 1.0Gy group were 80% vs 40% and 75% vs 40%, respectively. No acute radiation-induced toxicity MESHD was recorded. Conclusions: LD-WLI with a single 0.5Gy fraction seems to be a more appropriate dose to warrant further evaluation in a large-scale, randomized trial.

    Is there a correlation between pulmonary inflammation MESHD index with COVID-19 disease severity and outcome?

    Authors: Aliae Mohamed-Hussein; Islam Galal; Mohammed Mustafa Abdel Rasik Mohamed; Howaida Abd Elaal; Karim ME Aly; Shaikha Sami Abushaikha; Mujeeb Chettiyam Kandy; John Gibb; Sue VandeWoude; Robyn Esterbauer; Samantha K Davis; Helen E Kent; Francesca L Mordant; Timothy E Schlub; David L Gordon; David S Khoury; Kanta Subbarao; Deborah Cromer; Tom P Gordon; Amy W Chung; Miles P Davenport; Stephen J Kent

    doi:10.1101/2020.09.09.20182592 Date: 2020-09-10 Source: medRxiv

    Rational: the radiologic pulmonary inflammatory index (PII) may be used as early predictor of inflammation MESHD as laboratory assessments in COVID-19. The purpose of this study was to compare the clinical and radiological features between the cases of COVID-19 necessitating ICU and those who did not, and to correlate the PII with other inflammatory markers and outcome. Patients and methods: This study included 72 patients with confirmed COVID-19. Their electronic records of were retrospectively revised and the demographic, clinical, laboratory, HRCT data, PII and the outcomes of the patients were analyzed. Results: They were 50/50% males TRANS/ females TRANS, mean age TRANS was 47.1 (16.8). During their stay, 15.3% necessitated ICU admittance, 68% cured, 9 cases referred and five cases (6.9%) died. The baseline lesions identified were ground glass opacification in (93%), higher PII and >3 lobes affection were considerably recorded in those who required ICU (P= 0.041 and 0.013). There were correlations between PII with age TRANS (r=0.264, P=0.031), ferritin (r=0.225, P=0.048) and D Dimer (r=0.271, P=0.043). Conclusions: The use of PII together with clinical and laboratory data may be valuable in defining the inflammatory state of COVID-19. It was correlated with other inflammatory indices as D dimer, ferritin even before clinical deterioration.

    Convalescent plasma SERO as potential therapy for severe COVID-19 pneumonia HP pneumonia MESHD.

    Authors: Ricardo Valentini; Juan Dupont; Jose Fernandez; Jorge Solimano; Fernando Palizas; Dardo Riveros; Pablo Saul; Laura Dupont; Juan Medina; Viviana Falasco; Florencia Fornillo; Julia Laviano; Daniela Maymo; Daniel Gotta; Alfredo Martinez; Pablo Bonvehi

    doi:10.1101/2020.09.01.20184390 Date: 2020-09-07 Source: medRxiv

    At the beginning of the COVID-19 pandemic, there was high mortality and a lack of effective treatment for critically ill MESHD patients. Build on the experience in argentine hemorrhagic fever MESHD fever HP with convalescent plasma SERO, we incorporated 90 patients into a multicenter study, and 87 were evaluable. We collected 397 donations from 278 convalescent donors. Patients received plasma SERO with an IgG concentration of 0.7-0.8 (measured by Abbott chemiluminescence) for every 10 kg of body weight. Survival during the first 28 days was the primary objective. 77% were male TRANS, age TRANS 54 (+/-15.6 y/o (range 27-85); body mass index 29.7 +/-; 4,4; hypertension HP 39% and diabetes 20%; 19.5% had an immunosuppression condition; 23% were healthcare workers. Plasma SERO was administered to 55 patients (63%) on spontaneous breathing with oxygen supplementation (mainly oxygen mask with reservoir bag in 80%), and 32 patients (37%) were infused on mechanical ventilation. The 28-day survival rate was 80%, with 91% in patients infused on spontaneous breathing and 63% in those infused on mechanical ventilation (p = 0.0002). There was a significant improvement in the WHO pneumonia HP clinical scale at 7 and 14 days, and in PaO2 / FiO2, ferritin and LDH, in the week post-infusion. We observed an episode of circulatory volume overload and a febrile reaction, both mild. Convalescent plasma SERO infusions are feasible, safe, and potentially effective, especially before requiring mechanical ventilation, and are an attractive clinical option for treating severe forms of COVID-19 until other effective therapies become available.

    G6PD deficiency MESHD and severity of COVID19 pneumonia HP pneumonia MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome: tip of the iceberg?

    Authors: Jihad G. Youssef; Faisal Zahiruddin; George Youssef; Sriram Padmanabhan; Joe Ensor; Sai Ravi Pingali; Youli Zu; Sandeep Sahay; Swaminathan P. Iyer

    doi:10.21203/rs.3.rs-72639/v1 Date: 2020-09-05 Source: ResearchSquare

    The severe pneumonia HP pneumonia MESHD caused by human coronavirus (hCoV)-SARS-CoV-2 has inflicted heavy causalities, especially among the elderly TRANS and those with comorbid illnesses irrespective of age TRANS. The high mortality in African Americans and males TRANS, in general, raises concern for a possible X-linked mediated process that could affect viral pathogenesis and the immune system. We hypothesized that G6PD, the most common X-linked enzyme deficiency MESHD associated with redox status, may have a role in the severity of pneumonia HP pneumonia MESHD. A retrospective chart review was performed in hospitalized patients with COVID19 pneumonia HP pneumonia MESHD needing supplemental oxygen. A total of 17 patients were evaluated: six with G6PD deficiency MESHD and 11 with normal levels. The two groups (normal and G6PD def) were comparable in terms of age TRANS, sex and comorbidities and laboratory parameters LDH, IL-6, CRP, and ferritin. Thirteen patients needed ventilatory support, with 6 in the G6PD group (83% vs. 72%). The main differences indicating increasing severity in the G6PD def group included G6PD levels (12.2 vs. 5.6, P=0.0002), PaO2/FiO2 ratio (159 vs. 108, P=0.05), days before intubation (2.5 vs. 4.8 P= 0.03), days on mechanical ventilation (10.25 vs. 21 days P=0.04), hemoglobin level (10 vs. 8.1 P=0.03) and hematocrit (32 vs. 26 P=0.015). Only one patient with G6PD deficiency MESHD died; 16 were discharged home. Our clinical series ascribes a possible biological role for G6PD deficiency MESHD in SARS-CoV2 viral proliferation. It is imperative that further studies be performed to understand the interplay between the viral and host factors in G6PD deficiency MESHD that may lead to disparity in outcomes. 

    Risk Factors For COVID-19 Positivity in Hospitalized Patients in A Low Prevalence SERO Setting

    Authors: Iris Zohar; Orna Schwartz; Debby Ben David; Margarita Mashavi; Mohamad Aboulil; Orit Yossepowitch; Shirley Shapiro Ben David; ‪Yasmin Maor‬‏

    doi:10.21203/rs.3.rs-72761/v1 Date: 2020-09-05 Source: ResearchSquare

    Background: Identifying hospitalized patients with Coronavirus disease MESHD 2019 (COVID-19) in a low prevalence SERO setting is challenging.  We aimed to identify differences between COVID-19 positive and negative patients. Methods: Hospitalized patients with respiratory illness MESHD, or fever HP fever MESHD, were isolated in the emergency room and tested for COVID-19. Patients with a negative PCR and low probability for COVID-19 were taken out of isolation. Patients with a higher probability for COVID-19 remained in isolation during hospitalization and were retested after 48 hours. Risk factors for COVID-19 were assessed using logistic regression. Results: 254 patients were included, 37 COVID-19-positive (14.6%) and 217 COVID-19-negative (85.4%). Median age TRANS was 76 years, 52% were males TRANS. In a multivariate regression model, variables significantly associated with COVID-19 positivity were exposure to a confirmed COVID-19 case, length of symptoms before testing, bilateral and peripheral infiltrates in chest X-ray, neutrophil count within the normal range, and elevated LDH. In an analysis including only patients with pneumonia HP pneumonia MESHD (N=78, 18 positive for COVID-19), only bilateral and peripheral infiltrates, normal neutrophil count and elevated LDH were associated with COVID-19 positivity. Conclusions: The clinical presentation of COVID-19 positive and negative patients is similar, but radiographic and laboratory features may help to identify COVID-19 positive patients and to initiate quick decisions regarding isolation.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.